

# **GUIDELINES FOR LIVER TRANSPLANTATION IN PATIENTS WITH HIV INFECTION**

**April 2005**

**John O'Grady<sup>1</sup>, Chris Taylor<sup>1</sup>,  
Edited by Gary Brook<sup>2</sup>**

**Written on behalf of the British HIV Association and The UK and Ireland Liver  
Transplantation Centres and reviewed and endorsed by British  
Transplantation Society Standards Committee**

<sup>1</sup>King's College Hospital, London, <sup>2</sup>Central Middlesex Hospital London.

This document was written following a consensus meeting of specialists in the field of HIV and liver transplantation June 2004 (attendees listed in appendix)

## **Contents**

<b>1.0</b>	<b>Key recommendations</b>	<b>2</b>
<b>2.0</b>	<b>Audit standards</b>	<b>4</b>
<b>3.0</b>	<b>Background</b>	<b>5</b>
<b>4.0</b>	<b>Indications for liver transplantation</b>	<b>6</b>
	<b>4.1 Chronic liver disease and cirrhosis</b>	<b>6</b>
	<b>4.2 Hepatocellular carcinoma</b>	<b>7</b>
<b>5.0</b>	<b>Contraindications for liver transplantation</b>	<b>8</b>
<b>6.0</b>	<b>HIV-specific issues</b>	<b>9</b>
<b>7.0</b>	<b>Post-transplantation</b>	<b>10</b>
<b>8.0</b>	<b>National database</b>	<b>10</b>
<b>9.0</b>	<b>References</b>	<b>11</b>
	<b>Appendix I: list of consensus meeting participants</b>	<b>14</b>

## 1.0 Key Recommendations

Levels of evidence:

I = Meta-analysis or RCT

II = Other good quality trial

III = Observational studies/ Case Reports

IV = Expert Opinion

1. Given the improved prognosis of HIV in recent years, HIV-positive patients should be considered for liver transplantation where necessary (III)
2. Indications for transplantation include:
  - a. acute liver failure (III)
  - b. decompensated liver disease with ascites, encephalopathy (having excluded HIV related dementia) or problematic varices and poor synthetic function e.g. albumin <30g/l, INR >1.5 and elevated serum bilirubin e.g. >50umol/l (III)
  - c. hepatocellular carcinoma detected during regular tumour surveillance (recommended at least 6 monthly in all patients with cirrhosis) and meeting the Milan criteria (III)
3. Given the lag time between referral for assessment and liver transplantation (currently about one year), patients should be referred to a transplantation centre as early as possible (IV).
4. Patients with hepatocellular carcinoma who are being considered for liver transplantation should not have a needle biopsy due to the significant rate of needle-track seeding leading to recurrence post-transplant (III)
5. Patients being considered for transplantation should have a prognosis (excluding the liver disease) of 50% survival for 5 years (III)

6. HIV-specific parameters that should pertain include (III):
  - a. CD4 counts >200 cells/ul or >100 cells/ul in the presence of portal hypertension,
  - b. Absence of HIV viraemia,
  - c. Absence of AIDS defining illness after immune reconstitution,
  - d. Antiretroviral therapeutic options available if the HIV disease reactivates.
7. Absolute contraindications to transplantation include (II):
  - a. Alcohol-related liver disease without total abstinence for six months
  - b. Currently injecting intravenous drug use
  - c. Cholangiocarcinoma
  - d. Extrahepatic malignancy,
  - e. Uncontrolled extrahepatic sepsis e.g. endocarditis
  - f. Total thrombosis of porto-mesenteric system
  - g. Severe pulmonary hypertension (mean pulmonary pressure >50-55 mmHg).
8. A relatively recent diagnosis of non-HIV related malignancy does not necessarily contraindicate liver transplantation but the duration of recurrence free survival required before transplantation is varied (ranges from 1-5 years) and is determined by classifications based on the Penn registry data (IV).
9. Relative contraindications to transplantation include malnutrition, cardio-pulmonary disease, chronic renal impairment or poor motivation (II).
10. Calcineurin inhibitors interact with drugs in the HAART regimens. It is essential that no alterations are made to the HAART therapy without consultation with the host transplant centre (III). Antiretroviral and immunosuppressive drug levels may need to be monitored.

11. Given that donated livers are a scarce resource, the outcome of transplantation needs to be considered carefully before accepting someone onto a waiting list. Currently the outcome for patients transplanted for hepatitis C/HIV co-infection is worse than other causes due to accelerated disease. The outcome of liver transplantation in hepatitis B infection and other indications are in line with non-HIV infected liver transplant recipients over the first 3-5 years (III)
12. Patients have significant emotional, psychological and counselling needs that need to be met both before and after transplantation (II).
13. There is a need for a national database of patients considered for transplantation to gauge access and outcomes (IV).

## **2.0 Audit Standards**

1. All patients meeting the criteria for liver transplantation as defined in these guidelines should be discussed with and referred to the regional liver transplantation centre and this should be documented in their case notes.
2. All patients considered for transplantation should be included on a national database once this is in place.

## **3.0 Background**

The prognosis of HIV has greatly improved in the past ten years such that currently, HIV+ patients have a similar prognosis to those with type II diabetes [1-3]. Liver disease has emerged as a significant cause of morbidity and mortality in HIV infected patients in line with the dramatic improvement in survival in the HAART era [3-6]. This is especially important given that the rate of co-infection of HIV and hepatitis B or C is 5-10% in the UK and considerably higher elsewhere [6-8]. In the non-HIV population liver

transplantation has become a standard therapy for a wide range of liver diseases, although organ shortage means that only a minority of patients with liver disease ultimately receive transplants [9]. In the UK it is estimated that about 5 out of every 6 patients who die with liver disease are not considered for liver transplantation.

Guidelines have been developed to select patients for liver transplantation that reflect the reality of the donor pool and aim to maximise the benefit of the scarce resource [10,11]. However, these guidelines are not set in stone and are undergoing a constant process of refinement. HIV seropositivity is a case in point and was until recently almost universally considered to be an absolute contraindication to transplantation. A limited but significant number of liver transplant programmes no longer consider this to be the case (12-15).

The global experience with liver transplantation in HIV infected individuals currently numbers in the region of 150-200 cases but is increasing quite rapidly (12-15).

Approximately half of these cases have been described in the world literature. This experience has established the feasibility of liver transplantation in HIV infected patients although with a number of important caveats and the need for adjustments to standard protocols (12-17). Hepatitis C re-infection of the transplanted liver is the issue of most concern to date with broad recognition that accelerated disease is a feature in some patients (15). However, this scenario is not unique to patients with HIV infection and the precise scale of the problem remains to be defined with more experience. Broadly the outcome of liver transplantation in hepatitis B infection and other indications are in line with non-HIV infected liver transplant recipients over the first 3-5 years (12-17).

## 4.0 Indications for liver transplantation

The indications for liver transplantation include those directly related to the HIV infection itself or its mode of acquisition as well as diseases occurring incidentally in patients who also have HIV (12-17). The former category include:

- hepatitis C
- hepatitis B
- drug hepatotoxicity (including acute liver failure).

### 4.1 Chronic liver disease and cirrhosis

In patients with chronic liver disease and cirrhosis the main indications for liver transplantation are (18):

- decompensated liver disease with ascites, encephalopathy (important to exclude HIV related dementia) or problematic varices,
- poor synthetic function e.g. albumin <30g/l, INR >1.5 and elevated serum bilirubin e.g. >50umol/l
- hepatocellular carcinoma detected during regular tumour surveillance (recommended at least 6 monthly in all patients with cirrhosis).

The guidelines above need to be adjusted for the likely lag time between referral for assessment and the transplant actually taking place. This is increasing quite quickly in the UK at present (9, 18, 19) and can be up to one year or greater. Patient characteristics associated with longer waiting times include blood group O (20) and small stature.

### 4.2 Hepatocellular carcinoma

The selection criteria for hepatocellular carcinoma are normally what are referred to as the Milan criteria (21-24). These are:

- no more than 3 tumour nodules
- no nodule more than 5cm in diameter
- absence of macroscopic portal vein invasion
- absence of recognisable extrahepatic disease (lymphadenopathy may complicate assessment in patients with HIV).

A few centres are accepting patients for liver transplantation with so called 'extended criteria' or UCSF criteria (22-4) that accept single tumours of up to 6.5cm in diameter as long as the cumulative diameters of all tumours do not exceed 8cm. Patients with hepatocellular carcinoma do not receive any priority in the UK and these patients may need therapy to stabilise the disease while awaiting transplantation, usually with TACE (transarterial chemoembolisation) (25,26). It is important not to biopsy any hepatocellular carcinoma if the patient is still under consideration for liver transplantation as seeding of cells along the track of the biopsy needle has been the only cause of recurrent disease in some patients (27,28).

## **5.0 Contraindications for liver transplantation**

Some pertinent specific issues include the following (9-11):

- There is no specific upper age limit for transplantation but in assessing individual patients the guideline operative in the UK is that the patients should have at least a 50% chance of being alive 5 years after the transplant.
- Patients in whom alcohol is the cause or a co-factor in the cause of the liver disease must abstain from alcohol for at least 6 months before being transplanted and commit themselves to total abstinence afterwards. Some centre allow patients to go on the waiting list before the 6 month period is completed to avoid excessively long waiting-times.

- Current intravenous drug use is universally seen as an absolute contraindication to liver transplantation. Patients who are stable on methadone or use cannabis are not absolutely excluded from transplantation.
- A relatively recent diagnosis of non-HIV related malignancy does not necessarily contraindicate liver transplantation but the duration of recurrence free survival required before transplantation is varied (ranges from 1-5 years) and is determined by classifications based on the Penn registry data.

Current absolute contraindications to transplantation include:

- cholangiocarcinoma,
- extra-hepatic malignancy,
- uncontrolled extra-hepatic sepsis e.g. endocarditis
- total thrombosis of porto-mesenteric system
- severe pulmonary hypertension (mean pulmonary pressure >50-55 mmHg).

Factors that cause concern and may contribute to a decision not to accept a patient on the waiting list include:

- malnutrition,
- cardio-pulmonary disease,
- chronic renal impairment,
- poor motivation.

## **6.0 HIV specific issues (13-17)**

Current practice is targeting liver transplantation at patients with:

- CD4 counts >200 cells/ul or >100 cells/ul in the presence of portal hypertension,
- absence of viraemia,
- absence of AIDS defining illness after immune reconstitution,

- therapeutic options available if HIV disease reactivates.

These criteria are somewhat empirical and may well change with expanded experience.

## **7.0 Post-transplantation**

- Standard immunosuppression protocols are applied and there is little data yet that any specific regimens are better or worse in HIV infected patients than in non-infected recipients.
- Bacterial, viral and fungal sepsis profiles seem to be similar to non-HIV infected recipients.
- Calcineurin inhibitors interact with drugs in the HAART regimens (29,30). The most important is effect of protease inhibitors reducing metabolism of calcineurin inhibitors (tacrolimus and cyclosporine) resulting in greatly decreased requirements (some patients require 1-2% of standard dose). It is essential that no alterations be made to the HAART therapy without consultation with the host transplant centre.
- Patients have significant emotional, psychological or counselling needs both pre- and post-transplantation. Preparation and emotional support, together with communication around prognosis, ramifications, future adaptation and quality of life are issues that may need attention. All studies show a marked improvement in quality of life, especially related to physical function, in HIV-negative patients who are successfully transplanted [31,32].

## 8.0 National database of HIV-positive individuals assessed for liver transplantation

- Given the rapidly evolving knowledge base in terms of selection of suitable candidates and outcomes it is important to monitor the situation closely through a nationally coordinated database.
- This would hold information on patients suitable for transplantation, time taken before transplantation is performed and outcomes for those transplanted and those who were not.
- Such a database would be an important measure of access to transplantation.

## 9.0 References

1. Yudkin JS, Beran D. Prognosis of diabetes in the developing world. *Lancet* 2003;362:1420
2. Roper NA, Bilous RW, Kelly WF *et al.* Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. *Diabetes Care* 2002;25:43-8
3. Mocroft A, Brettle R, Kirk O *et al.* Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. *AIDS* 2002;16:1663-71
4. Thio CL, Seaberg EC, Skolasky R *et al.* Liver disease mortality in HIV-HBV co-infected persons. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, Abstract 656.
5. Benhamou Y, Bochet M, Di Martino V *et al.* Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. *Hepatology*, 1999, 30, 1054–1058.
6. Soto B, Sanchez-Quijano A, Rodrigo L *et al.* Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *J Hepatol*, 1997, 26, 1–5.
7. Rockstroh J, Konopnicki D, Soriano V *et al.* Hepatitis B and Hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004 Abstract 799.
8. Beck E J, Mandalia S, Leonard K *et al.* Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission. *Int J STD AIDS* 1996;7:34-8
9. Rudge CJ, Fuggle SV, Burbidge KM. Geographic disparities in access to organ transplantation in the United Kingdom. *Transplantation* 2003;76:1395-8
10. Devlin J, O-Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. *British Society of Gastroenterology. Gut* 1999;45 (Suppl 6):VI1-VI22
11. Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. *Lancet* 1999;354:1636-9
12. Soriano V, Miró JM, García SJ *et al.* Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. *J Viral Hepat* 2004;11:2-17

13. Ragni MV,, Belle SH, Im-Kyung AH *et al.* Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis* 2003;188:1412-20
14. Fung J, Eghtesad B, Patel TK *et al.* Liver transplantation in patients with HIV infection. *Liver Transpl* 2004;10(Suppl 2):S39-53
15. Norris S, Taylor C, Muiresan P *et al.* Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. *Liver Transpl* 2004;10:1271-8
16. Neff G, Bonham A, Tzakis AG *et al.* Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl* 2003;9:239-47
17. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. *Transplantation* 2003;75:425-9
18. Adam R, McMaster P, O-Grady JG *et al.* Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. *Liver Transpl* 2003;9:1231-43
19. Neuberger J. Hope or efficacy in donor liver allocation? *Transplantation* 2001;72:1173-6.
20. Everhart JE, Lombardero M, Detre KM *et al.* Increased waiting time for liver transplantation results in higher mortality. *Transplantation* 1997;64:1300-6
21. Ravaioli M, Ercolani G, Cescon M *et al.* Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. *Liver Transpl* 2004;10:1195-202
22. Fernández JA, Robles R, Marin C *et al.* Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? *Transplant Proc* 2003;35:1818-20.
23. Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. *Aliment Pharmacol Ther* 2003;17(Suppl 2):130-7
24. Yao FY, Ferrell L, Bass NM *et al.* Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl* 2002;8:765-74
25. Fisher RA, Maluf D, Cotterell AH *et al.* Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. *Clin Transplant* 2004;18:502-12
26. Wong LL, Tanaka K, Lau L *et al.* Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. *Clin Transplant* 2004;18:227-34
27. Takamori R, Wong LL, Dang C. *et al.* Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? *Liver Transpl* 2000;6:67-72
28. Caturelli E, Ghittoni G, Roselli P *et al.* Fine needle biopsy of focal liver lesions: the hepatologist's point of view. *Liver Transpl* 2004;10(Suppl 1):S26-9
29. Jain AKB, Venkataramanan R, Shapiro R *et al.* The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. *Liver Transpl* 2002;8:841-5
30. Casanovas TT. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. *Transplant Proc* 2004;36(2 Suppl):291S-294S
31. Bravata DM, Olkin I, Barnato AE *et al.* Health-related quality of life after liver transplantation: a meta-analysis. *Liver Transpl Surg.* 1999;5:318-31.
32. Blanch J, Sureda B, Flavia M *et al.* Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. *Liver Transpl.* 2004;10:228-34.

## **Appendix I**

### **Participants at the Liver Transplantation Consensus Meeting, 18<sup>th</sup> June 2004, London.**

Dr Michael Allison, Addenbrook's Hospital, Cambridge

Dr Guy Baily, Royal London Hospital

Dr Andy Bathgate, Edinburgh Royal Infirmary

Dr Sanjay Bhagani, Royal Free Hospital, London

Dr Gary Brook, Central Middlesex Hospital, London

Prof Andrew Burroughs, Royal Free Hospital, London

Prof Brian Gazzard, Chelsea & Westminster Hospital, London

Dr Richard Gilson, Royal Free and UCMS, London

Dr Mia Huengsberg, Whittall Street Clinic, Birmingham

Dr Ranja Kulasegaram, St Thomas' Hospital, London

Dr Clifford Leen, Western General Hospital, Edinburgh

Dr Aidan McCormick, St Vincent's Hospital, Dublin

Dr Geoffrey Haydon, Queen Elizabeth Hospital, Birmingham

Dr Mark Nelson, Chelsea & Westminster Hospital, London

Dr John O'Grady, King's College Hospital, London

Dr Caroline Sabin, Royal Free & UCMS, London

Dr Gabrielle Scapak, Royal Free Hospital, London

Dr Christopher Taylor, King's College Hospital, London

Dr Edmund Wilkins, North Manchester General Hospital

Mr Nigel Hughes, Gilead Sciences Limited (Observer)

Dr Shafique Virani, Roche Products Limited (Observer)

The costs of the meeting were met through unconditional educational grants from Gilead Sciences Limited and Roche Products Limited.